AlphaCore Capital LLC Raises Stock Holdings in Quest Diagnostics Incorporated $DGX

AlphaCore Capital LLC increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 219.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,597 shares of the medical research company’s stock after purchasing an additional 3,157 shares during the quarter. AlphaCore Capital LLC’s holdings in Quest Diagnostics were worth $798,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in DGX. JFS Wealth Advisors LLC lifted its stake in shares of Quest Diagnostics by 114.3% during the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after purchasing an additional 80 shares during the last quarter. Harbor Investment Advisory LLC raised its stake in Quest Diagnostics by 113.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after buying an additional 83 shares during the last quarter. McIlrath & Eck LLC purchased a new stake in Quest Diagnostics in the fourth quarter valued at about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Quest Diagnostics in the third quarter valued at about $33,000. Finally, ORG Partners LLC raised its stake in Quest Diagnostics by 66.1% in the fourth quarter. ORG Partners LLC now owns 211 shares of the medical research company’s stock valued at $37,000 after buying an additional 84 shares during the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DGX has been the topic of a number of research reports. Citigroup increased their price objective on Quest Diagnostics from $190.00 to $215.00 and gave the company a “neutral” rating in a report on Tuesday, February 10th. Robert W. Baird raised their target price on Quest Diagnostics from $224.00 to $229.00 and gave the stock a “neutral” rating in a report on Wednesday, April 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $225.00 target price on shares of Quest Diagnostics in a report on Tuesday, April 21st. Evercore set a $225.00 target price on Quest Diagnostics in a report on Tuesday, April 21st. Finally, Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Saturday, April 25th. Seven equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and an average target price of $216.58.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock opened at $189.87 on Tuesday. Quest Diagnostics Incorporated has a one year low of $164.65 and a one year high of $213.50. The company has a market cap of $21.02 billion, a price-to-earnings ratio of 20.98, a PEG ratio of 2.22 and a beta of 0.60. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.08 and a current ratio of 1.18. The business’s 50 day moving average price is $195.43 and its 200 day moving average price is $190.07.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.37 by $0.13. The company had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.94 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, research analysts predict that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics announced that its Board of Directors has initiated a share buyback program on Tuesday, February 10th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 4.7% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In related news, SVP Michael E. Prevoznik sold 3,878 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total value of $799,682.38. Following the sale, the senior vice president owned 37,557 shares in the company, valued at approximately $7,744,628.97. The trade was a 9.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Catherine T. Doherty sold 5,558 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total value of $1,146,115.18. Following the transaction, the executive vice president directly owned 67,122 shares of the company’s stock, valued at $13,841,227.62. The trade was a 7.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 18,421 shares of company stock worth $3,790,214 in the last three months. 0.88% of the stock is owned by insiders.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.